Psychedelic Bulletin: Are REMS Patents the Next Frontier in the Psychedelics Patent Skirmish? Johns Hopkins Researcher Scores U.S. Government Grant

As psychedelic therapies inch closer to potential approvals, it’s prudent to begin thinking about what strings may be attached to such approvals. In the U.S., the Food and Drug Administration (FDA) often mandates the provision of Risk Evaluation and Mitigation Strategies (REMS) programs alongside (or, after) the approval of a potentially dangerous therapeutic, in an attempt to ensure the benefits…

Source